Anticonvulsant Profiles of Three Hemorphin-4 Analogs with Rhodamine B in Mice.

IF 4.3 3区 医学 Q2 CHEMISTRY, MEDICINAL
Pharmaceuticals Pub Date : 2025-05-01 DOI:10.3390/ph18050673
Jana Tchekalarova, Miroslav Rangelov, Ivan Iliev, Nadezhda Todorova, Tsveta Stoyanova, Lian Nedelchev, Petar Todorov
{"title":"Anticonvulsant Profiles of Three Hemorphin-4 Analogs with Rhodamine B in Mice.","authors":"Jana Tchekalarova, Miroslav Rangelov, Ivan Iliev, Nadezhda Todorova, Tsveta Stoyanova, Lian Nedelchev, Petar Todorov","doi":"10.3390/ph18050673","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: Hemorphins, considered to be bioactive atypical oligopeptides, are products of hemoglobin metabolism. Recently, our team reported the synthesis and characterization of three N-modified analogs of hemorphin-4 (H4) with rhodamine B (Rh). In the present study, the Rh-1, Rh-2, and Rh-3 compounds were intracerebroventricularly infused at doses of 1, 2.5, 5, and 10 µg/5 µL, respectively, and evaluated for their antiseizure activity in 6-Hz and maximal electroshock (MES) tests and in a pentylenetetrazol (PTZ)-induced kindling model in mice. Phenytoin and diazepam were used as the reference drugs. The role of opioid receptors (ORs) underlying their mechanism of action was also evaluated in silico and pharmacologically. <b>Results</b>: The three Rh-H4 compounds showed a good safety profile at a concentration of 100 µg/mL in the mouse embryonic fibroblasts. They suppressed psychomotor seizures and seizure spreading as follows: Rh-1 at doses of 5 and 10 µg/5 µL, Rh-2 at the highest dose, and Rh-3 at doses of 1-10 µg/5 µL, respectively. Administered at doses of 5 µg/5 µL (Rh-1 and Rh-3) and 10 µg/5 µL (Rh-2), the compounds suppressed clonic seizures in the kindled mice comparable to the reference drug diazepam. A combination of selective delta (DOR), kappa (KOR), and mu (MOR) OR antagonists with the highest doses of the Rh-1, Rh-2, and Rh-3 compounds was used to elucidate the possible role of ORs in the underlying mechanism related to their protective activity against seizure spread. Only the selective DOR antagonist, natrindole, suppressed the effect of the Rh-1 peptide analog on seizures. The OR antagonist naloxone prevented the antiseizure activity of Rh-1 in the kindled mice. The results of docking analysis also showed the model-specific interaction of the three Rh-H4 compounds with the OR. <b>Conclusions</b>: Our results suggest that the antiseizure activity of Rh-1 is mediated by the OR, and in particular by the DOR, while the mechanism underlying the antiseizure effect of Rh-3 is more complex and may involve other receptors.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12115103/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18050673","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: Hemorphins, considered to be bioactive atypical oligopeptides, are products of hemoglobin metabolism. Recently, our team reported the synthesis and characterization of three N-modified analogs of hemorphin-4 (H4) with rhodamine B (Rh). In the present study, the Rh-1, Rh-2, and Rh-3 compounds were intracerebroventricularly infused at doses of 1, 2.5, 5, and 10 µg/5 µL, respectively, and evaluated for their antiseizure activity in 6-Hz and maximal electroshock (MES) tests and in a pentylenetetrazol (PTZ)-induced kindling model in mice. Phenytoin and diazepam were used as the reference drugs. The role of opioid receptors (ORs) underlying their mechanism of action was also evaluated in silico and pharmacologically. Results: The three Rh-H4 compounds showed a good safety profile at a concentration of 100 µg/mL in the mouse embryonic fibroblasts. They suppressed psychomotor seizures and seizure spreading as follows: Rh-1 at doses of 5 and 10 µg/5 µL, Rh-2 at the highest dose, and Rh-3 at doses of 1-10 µg/5 µL, respectively. Administered at doses of 5 µg/5 µL (Rh-1 and Rh-3) and 10 µg/5 µL (Rh-2), the compounds suppressed clonic seizures in the kindled mice comparable to the reference drug diazepam. A combination of selective delta (DOR), kappa (KOR), and mu (MOR) OR antagonists with the highest doses of the Rh-1, Rh-2, and Rh-3 compounds was used to elucidate the possible role of ORs in the underlying mechanism related to their protective activity against seizure spread. Only the selective DOR antagonist, natrindole, suppressed the effect of the Rh-1 peptide analog on seizures. The OR antagonist naloxone prevented the antiseizure activity of Rh-1 in the kindled mice. The results of docking analysis also showed the model-specific interaction of the three Rh-H4 compounds with the OR. Conclusions: Our results suggest that the antiseizure activity of Rh-1 is mediated by the OR, and in particular by the DOR, while the mechanism underlying the antiseizure effect of Rh-3 is more complex and may involve other receptors.

三种Hemorphin-4类似物与罗丹明B的抗惊厥作用。
背景/目的:Hemorphins被认为是具有生物活性的非典型寡肽,是血红蛋白代谢的产物。最近,我们的团队报道了三种含罗丹明B (Rh)的n修饰的hemorphin-4 (H4)类似物的合成和表征。在本研究中,Rh-1、Rh-2和Rh-3化合物分别以1、2.5、5和10µg/5µL的剂量注入脑室内,并在6hz和最大电休克(MES)试验和戊四唑(PTZ)诱导的小鼠点火模型中评估其抗癫痫活性。以苯妥英和地西泮为对照药。阿片受体(ORs)在其作用机制下的作用也在计算机和药理学上进行了评估。结果:3种Rh-H4化合物在100 μ g/mL浓度下对小鼠胚胎成纤维细胞具有良好的安全性。他们抑制精神运动发作和发作扩散如下:Rh-1剂量为5和10µg/5µL, Rh-2剂量最高,Rh-3剂量为1-10µg/5µL。给药剂量为5µg/5µL (Rh-1和Rh-3)和10µg/5µL (Rh-2)的化合物抑制点燃小鼠的阵挛性发作,效果与参比药物地西泮相当。选择性δ (DOR), kappa (KOR)和mu (MOR) OR拮抗剂与最高剂量的Rh-1, Rh-2和Rh-3化合物的组合被用来阐明ORs在其对癫痫发作扩散的保护活性相关的潜在机制中的可能作用。只有选择性DOR拮抗剂纳曲多抑制了Rh-1肽类似物对癫痫发作的作用。OR拮抗剂纳洛酮可阻止点燃小鼠Rh-1的抗癫痫活性。对接分析结果还显示了3种Rh-H4化合物与OR的模型特异性相互作用。结论:Rh-1的抗癫痫活性是由OR,尤其是DOR介导的,而Rh-3的抗癫痫作用机制更为复杂,可能涉及其他受体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceuticals
Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.10
自引率
4.30%
发文量
1332
审稿时长
6 weeks
期刊介绍: Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信